Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
![AI](https://streamlined.nyc3.cdn.digitaloceanspaces.com/assets/ai-default.gif)
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Neurogene Inc.
Neurogene Inc. News
Neurogene Inc. Quantitative Score
![Website screenshot](https://streamlined.nyc3.cdn.digitaloceanspaces.com/website-screenshots/neurogene-com.webp)
About Neurogene Inc.
Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases. Its product candidate includes NGN-401, an investigational AAV9 gene therapy for the treatment of Rett syndrome; and NGN-101 to treat neuronal ceroid lipofuscinosis subtype 5 batten disease. The company is headquartered in New York, New York.
Neurogene Inc. Earnings & Revenue
Neurogene Inc. Financials
Table Compare
Compare NGNE metrics with: | |||
---|---|---|---|
Earnings & Growth | NGNE | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | NGNE | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | NGNE | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | NGNE | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Neurogene Inc. Income
Neurogene Inc. Balance Sheet
Neurogene Inc. Cash Flow
Neurogene Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
Metrics | Score |
---|---|
Discounted Cash Flows | Neutral |
Return on Equity | Strong Sell |
Return on Assets | Strong Sell |
Debt/Equity Ratio | Neutral |
Price/Earnings Ratio | Strong Sell |
Price/Book Ratio | Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
Neurogene Inc. Executives
Name | Role |
---|---|
Dr. Rachel L. McMinn Ph.D. | Founder, Executive Chair & Chief Executive Officer |
Ms. Christine Mikail Cvijic J.D. | President, Chief Financial Officer & Corporate Secretary |
Dr. Stuart Cobb Ph.D. | Chief Scientific Officer |
Mr. Arvind Sreedharan | Senior Vice President of Business Operations |
Mr. Ricardo Jimenez | Senior Vice President of Technical Operations |
Name | Role | Gender | Date of Birth | Pay |
---|---|---|---|---|
Dr. Rachel L. McMinn Ph.D. | Founder, Executive Chair & Chief Executive Officer | 1973 | 676.54K | |
Ms. Christine Mikail Cvijic J.D. | President, Chief Financial Officer & Corporate Secretary | Female | 1978 | 623.29K |
Dr. Stuart Cobb Ph.D. | Chief Scientific Officer | 1970 | 478.81K | |
Mr. Arvind Sreedharan | Senior Vice President of Business Operations | Male | -- | |
Mr. Ricardo Jimenez | Senior Vice President of Technical Operations | Male | -- |
Neurogene Inc. Insider Trades
Date | 14 Jun |
Name | Woods Robert Keith |
Role | Director |
Transaction | Acquired |
Type | A-Award |
Shares | 7700 |
Date | 14 Jun |
Name | PALEKAR ROHAN |
Role | Director |
Transaction | Acquired |
Type | A-Award |
Shares | 7700 |
Date | 14 Jun |
Name | BAFFI ROBERT |
Role | Director |
Transaction | Acquired |
Type | A-Award |
Shares | 7700 |
Date | 14 Jun |
Name | Noonberg Sarah B. |
Role | Director |
Transaction | Acquired |
Type | A-Award |
Shares | 7700 |
Date | 14 Jun |
Name | Freedland Cory S. |
Role | Director |
Transaction | Acquired |
Type | A-Award |
Shares | 7700 |
Date | Name | Role | Transaction | Type | Shares |
---|---|---|---|---|---|
14 Jun | Woods Robert Keith | Director | Acquired | A-Award | 7700 |
14 Jun | PALEKAR ROHAN | Director | Acquired | A-Award | 7700 |
14 Jun | BAFFI ROBERT | Director | Acquired | A-Award | 7700 |
14 Jun | Noonberg Sarah B. | Director | Acquired | A-Award | 7700 |
14 Jun | Freedland Cory S. | Director | Acquired | A-Award | 7700 |